Inhaled steroid therapy in chronic obstructive pulmonary disease.
Chronic obstructive pulmonary disease (COPD) remains difficult to manage. Patients with COPD present with progressive dyspnea; difficulty in stopping smoking; recurrent exacerbations; and, ultimately, respiratory failure. Because of the lack of proven treatments for COPD and because inhaled corticosteroids can prevent airway inflammation and permanent lung damage in patients with asthma, it has become common practice to prescribe inhaled corticosteroids for patients with COPD despite a lack of data suggesting that these agents have any long-term benefit in these patients. In the past 12 months, three randomized, double-blind, placebo-controlled clinical trials (the European Respiratory Society Study on Chronic Obstructive Pulmonary Disease, the Copenhagen City Lung Study, and the Inhaled Steroids in Obstructive Lung Disease study) designed to assess the long-term effect of inhaled corticosteroids in patients with varying severity of airway obstruction have been presented. The results of these studies have been disappointing; they show little to suggest that any long-term benefit is gained from using inhaled corticosteroids in most patients with COPD, whether they continue to smoke or not.
Whittaker
A J
AJ
Department of Respiratory Medicine, The Middlesex Hospital, London, United Kingdom.
Spiro
S G
SG
D000280:Administration, Inhalation; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D000730:Androstadienes / Q000627:therapeutic use; D019819:Budesonide / Q000627:therapeutic use; D000068298:Fluticasone; D005541:Forced Expiratory Volume; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000188:drug therapy*; D011237:Predictive Value of Tests; D011788:Quality of Life; D012720:Severity of Illness Index
D000305:Adrenal Cortex Hormones; D000730:Androstadienes; D005938:Glucocorticoids; D019819:Budesonide; D000068298:Fluticasone